- Trials with a EudraCT protocol (765)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
765 result(s) found for: Cancer Survival Rates.
Displaying page 1 of 39.
EudraCT Number: 2005-003327-39 | Sponsor Protocol Number: KKSH-14 | Start Date*: 2006-04-21 |
Sponsor Name:Martin-Luther-University | ||
Full Title: Integration of 3D-conformal, local radiotherapy (3DCRT) to metastatic sites in a paclitaxel weekly chemotherapy regimen in oligometastatic breast cancer patients: a phase I- and randomised phase II... | ||
Medical condition: oligometastatic breast cancer | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002717-35 | Sponsor Protocol Number: P170920J | Start Date*: 2018-12-13 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Non inferiority multicenter phase III randomized trial comparing preoperative chemotherapy only to chemoradiotherapy for locally advanced resectable rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE) | |||||||||||||
Medical condition: Adults ≥ 18 years with middle or low locally advanced resectable rectal carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001748-23 | Sponsor Protocol Number: SGM-LARRC | Start Date*: 2019-08-07 | ||||||||||||||||
Sponsor Name:Leiden University Medical Center | ||||||||||||||||||
Full Title: Multicenter, open-label, controlled, parallel arms clinical study on the performance of SGM-101, a fluorochrome-labeled anti-carcino-embryonic antigen (CEA) monoclonal antibody, for locally advance... | ||||||||||||||||||
Medical condition: Locally advanced rectal cancer Recurrent rectal cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001419-25 | Sponsor Protocol Number: GastricCHIMERAtrial | Start Date*: 2021-04-09 | |||||||||||
Sponsor Name:Jagiellonian University Medical College | |||||||||||||
Full Title: Preoperative intraperitoneal chemotherapy in adjuvant hyperthermia adjunctive therapy in advanced gastric cancer with high-risk of peritoneal recurrence - a multicentre randomized trial | |||||||||||||
Medical condition: Gastric Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-005187-34 | Sponsor Protocol Number: CCR4644 | Start Date*: 2017-09-11 |
Sponsor Name:The Royal Marsden NHS Foundation Trust | ||
Full Title: Stereotactic body radiotherapy with immunotherapy in early stage non-small cell lung cancer: tolerability and lung effects | ||
Medical condition: Non small-cell lung cancer (NSCLC) Stage: T1-3( ≤5cm)N0M0) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2010-021434-55 | Sponsor Protocol Number: FE 200486 CS35A | Start Date*: 2010-11-11 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring And... | |||||||||||||
Medical condition: Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: HU (Prematurely Ended) GB (Prematurely Ended) FI (Prematurely Ended) NL (Prematurely Ended) CZ (Completed) BE (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005142-29 | Sponsor Protocol Number: UC-0107/1718 | Start Date*: 2018-08-30 |
Sponsor Name:UNICANCER | ||
Full Title: PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer | ||
Medical condition: Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment with a PD-1 or PD-L1 antagonist according to the European Marketing Authorisation in a first line or a second line | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005210-18 | Sponsor Protocol Number: EFFIPEC01 | Start Date*: 2021-03-28 | |||||||||||
Sponsor Name:Uppsala University | |||||||||||||
Full Title: EFFIPEC – Efficacy of Hyperthermic Intraperitoneal Chemotherapy Single-arm Phase I study, followed by an open-label, randomized, controlled registry-based Phase III trial | |||||||||||||
Medical condition: Colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004819-31 | Sponsor Protocol Number: IN-CRC-001 | Start Date*: 2021-05-19 | |||||||||||
Sponsor Name:IN3BIO | |||||||||||||
Full Title: A Phase I/II, multi-centre, open-label, adaptive design, umbrella study assessing the safety, tolerability, immunogenicity and efficacy of IN01 in combination with small-molecule inhibitors in two ... | |||||||||||||
Medical condition: colorectal cancer at a metastatic stage, eligible for a second line treatment and presenting with a constitutive BRAF or RAS mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003301-97 | Sponsor Protocol Number: GO41767 | Start Date*: 2020-04-15 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE... | ||||||||||||||||||
Medical condition: Small cell lung cancer (SCLC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) PL (Ongoing) AT (Ongoing) HU (Ongoing) BE (Ongoing) ES (Ongoing) GR (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002971-32 | Sponsor Protocol Number: PROICM2019-11PRA | Start Date*: 2020-07-27 |
Sponsor Name:Institut Regional du Cancer de Montpellier | ||
Full Title: A Double blind randomized phase III study of pravastatin vs placebo as primary prevention of severe subcutaneous breast fibrosis in hyper-radiosensitive identified patients with breast cancer | ||
Medical condition: Radio-induced fibrosis in breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-000366-36 | Sponsor Protocol Number: TLK286.3025 | Start Date*: 2006-06-07 | |||||||||||
Sponsor Name:Telik, Inc. | |||||||||||||
Full Title: Phase 3 randomized study of TLK286 (Telcyta™) in combination with liposomal doxorubicin (Doxil®/Caelyx®) versus liposomal doxorubicin (Doxil®/Caelyx®) as second-line therapy in platinum refractory ... | |||||||||||||
Medical condition: platinum refractory or resistant ovarian cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003819-56 | Sponsor Protocol Number: 26193789 | Start Date*: 2020-06-12 | |||||||||||||||||||||
Sponsor Name:Centre for Surgical Science | |||||||||||||||||||||||
Full Title: Effects of intravenous administered iron in non-anemic iron deficient patients with colorectal cancer. A double blinded clinical randomized trial. | |||||||||||||||||||||||
Medical condition: Iron-deficiency in colorectal cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000857-11 | Sponsor Protocol Number: 345-449 | Start Date*: 2016-05-27 |
Sponsor Name:Bank of Cyprus Oncology Centre | ||
Full Title: A Phase II study of Switch Maintenance Pembrolizumab in patients with Non Small Cell Lung Cancer (NSCLC) who do not progress after First Line Platinum Doublet Chemotherapy | ||
Medical condition: Non small cell lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CY (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001661-32 | Sponsor Protocol Number: VeTo | Start Date*: 2012-07-05 | |||||||||||||||||||||
Sponsor Name:Vejle Hospital, Dept. of Oncology | |||||||||||||||||||||||
Full Title: Veliparib (ABT888) and Topotecan (Hycamtin®) for Patients with Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer with Negative or Unknown BRCA Status | |||||||||||||||||||||||
Medical condition: Relapsed epithelial, platinum resistant ovarian cancer with negative or unknown BRCA status | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-022902-41 | Sponsor Protocol Number: BIG4-11/BO25126/TOC4939g | Start Date*: 2011-09-26 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in pa... | |||||||||||||
Medical condition: Patients with operable HER2-positive primary breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) HU (Ongoing) CZ (Completed) ES (Ongoing) FR (Ongoing) IE (Ongoing) SE (Ongoing) DK (Completed) SI (Ongoing) NL (Ongoing) BE (Ongoing) SK (Completed) AT (Trial now transitioned) IT (Ongoing) BG (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004433-26 | Sponsor Protocol Number: 3638 | Start Date*: 2016-05-04 | |||||||||||||||||||||
Sponsor Name:North Bristol NHS Trust | |||||||||||||||||||||||
Full Title: Zoledronic acid in the management of malignant pleural mesothelioma - a feasibility study | |||||||||||||||||||||||
Medical condition: Malignant pleural mesothelioma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-004102-27 | Sponsor Protocol Number: SCI-RP-Pan-P2-001 | Start Date*: 2008-02-20 | ||||||||||||||||
Sponsor Name:SciClone Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double Blind, Placebo Controlled, Phase II Study Evaluating the Efficacy and Safety of RP101 in Combination with Gemcitabine Administered as First-Line Treatment to Subjects with Unre... | ||||||||||||||||||
Medical condition: metastatic pancreatic cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Prematurely Ended) ES (Ongoing) NL (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001801-15 | Sponsor Protocol Number: FCO-HIP-2015-01 | Start Date*: 2015-10-08 | |||||||||||
Sponsor Name:FIBICO | |||||||||||||
Full Title: Multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced c... | |||||||||||||
Medical condition: Colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005003-32 | Sponsor Protocol Number: ORCHESTRA | Start Date*: 2012-06-14 | |||||||||||
Sponsor Name:VU University Medical Center, Department of Medical Oncology | |||||||||||||
Full Title: A randomized multicenter clinical trial for patients with multi-organ, colorectal cancer metastases comparing the combination of chemotherapy and maximal tumor debulking versus chemotherapy alone. | |||||||||||||
Medical condition: multi-organ metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.